Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414632 · ClinicalTrials.gov registry record · Early Phase 1
Transthyretin Cardiac Amyloidosis in HFpEF
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 287
- Enrollment target
NCT03414632: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03414632 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 287 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03414632, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 287 participants
- Enrollment target
Study Summary
To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).
Interventions
- DRUG 99mTc-PYP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2020-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03414632
The ClinicalTrials.gov registry entry for NCT03414632 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 99mTc-PYP is the first listed.
NCT03414632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03414632 about?
NCT03414632 is a clinical study titled "Transthyretin Cardiac Amyloidosis in HFpEF". To estimate the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among Heart Failure with Preserved Ejection Fraction (HFpEF) patients with increased LV wall thickness in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/C...
What is the current status of trial NCT03414632?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 287 participants. The study started on 2017-12-01. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03414632?
The interventions under investigation include: 99mTc-PYP (DRUG).
Who is sponsoring clinical trial NCT03414632?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.